Abrocitinib: What It Is and How It’s Studied
Quick summary Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor being studied for atopic dermatitis (eczema). The content below explains the condition, the JAK/STAT pathway, and a phase 3 study in adolescents. Medical...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor being studied for atopic dermatitis (eczema). The content below explains the condition, the JAK/STAT pathway, and a phase 3 study in adolescents.
Medical disclaimer: This article is for general educational purposes only. It does not replace advice from a doctor, pharmacist, or the official product information. Do not use this page to diagnose a condition or to make treatment changes.
What is abrocitinib?
Abrocitinib is an experimental once-daily oral JAK1 inhibitor developed by Pfizer for the treatment of atopic dermatitis, also called eczema. It has been studied as a way to help reduce inflammation and itch.
In the original content, abrocitinib is described as being investigated for use in people with moderate to severe atopic dermatitis, including adolescents.
Why is the JAK/STAT pathway important in eczema?
The JAK/STAT pathway is one of several signaling pathways involved in inflammation and pruritus, which means itch. In atopic dermatitis, multiple receptors and signaling cascades contribute to the skin inflammation and itching that people experience.
Because this pathway is involved in immune signaling, JAK inhibitors have been studied in inflammatory and immune-mediated diseases.
What did the JADE TEEN study look at?
The original article describes the JADE TEEN trial, an international phase 3 study conducted in several countries by a team from Rady’s Children’s Hospital, San Diego, and the Department of Dermatology and Pediatrics at the University of California, USA.
The study evaluated abrocitinib in adolescents with moderate to severe atopic dermatitis, along with topical therapy.
Who was included?
Eligible patients were 12 to 17 years old and had moderate to severe disease. The study used the following measures:
- Investigator’s Global Assessment (IGA) score greater than 3
- Eczema Area and Severity Index (EASI) score greater than 16
- Peak Pruritus Numeric Rating Scale (PP-NRS) score greater than 4
The PP-NRS is a scale from 0 to 10, where 0 means no itch and 10 means the worst itch imaginable.
What treatments were compared?
Participants were randomized 1:1:1 to receive one of the following for 12 weeks:
- Oral abrocitinib 200 mg plus topical therapy
- Oral abrocitinib 100 mg plus topical therapy
- Placebo plus topical therapy
Permitted topical treatments included emollients, low- and medium-potency topical steroids, topical calcineurin inhibitors, or crisaborole.
What outcomes were studied?
The primary endpoint was the percentage of patients who achieved:
- IGA score of 0/1, meaning clear or almost clear, and at least a 2-grade improvement in IGA score, and/or
- EASI75, meaning a 75% improvement in disease severity
A secondary outcome was a 4-point improvement from baseline in PP-NRS at weeks 2, 4, and 12.
What does this mean in plain language?
In simple terms, the study was designed to see whether abrocitinib, used with topical therapy, could improve eczema severity and reduce itch in adolescents with moderate to severe disease.
The original content states that abrocitinib and topical therapy led to significant improvements in disease severity in adolescents with moderate to severe atopic eczema.
Key points to verify with a clinician or official leaflet
If you are reading about abrocitinib for personal or professional reasons, it is important to check the latest official information for details such as:
- Whether the medicine is approved in your country
- Which age groups it is intended for
- How it is used in practice
- Potential risks, warnings, and monitoring requirements
- Whether it is appropriate alongside topical therapy or other treatments
These details can change over time and should be confirmed from official sources.
Frequently asked questions
▸ What is abrocitinib used for in the original article?
The article describes abrocitinib as being developed and studied for atopic dermatitis (eczema), especially moderate to severe disease.
▸ Is abrocitinib an oral medicine?
Yes. The original content describes it as an experimental once-daily oral JAK1 inhibitor.
▸ What age group was studied in JADE TEEN?
The study included adolescents aged 12 to 17 years with moderate to severe atopic dermatitis.
▸ What is the JAK/STAT pathway?
It is a signaling pathway involved in inflammation and itch. The original article notes that it plays an important role in eczema-related inflammation and pruritus.
▸ What topical treatments were allowed in the study?
The study allowed emollients, low- and medium-potency topical steroids, topical calcineurin inhibitors, and crisaborole.
Safety reminder: If you have eczema symptoms or are considering any treatment mentioned here, speak with a qualified healthcare professional. Only a clinician can interpret study results in the context of an individual patient, and only official prescribing information should guide use.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.